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Summary Some earlier studies based on relatively small data sets have suggested that the month of diagnosis
affects survival of breast cancer patients. This phenomenon has been suggested to be attributable to daylight-
related hormonal factors. Factors related to the holidays of both the medical personnel and the women
themselves might also provide the explanation. In this study we assessed the effect of the month of diagnosis
on the survival of 32,807 female breast cancer patients diagnosed in Finland in 1956-1985. Our results
indicate that the month of diagnosis is a significant prognostic factor after adjusting for age at diagnosis,
period of diagnosis, and stage at diagnosis. The adjusted relative excess risk of death was highest among those
diagnosed in July and August, and lowest in March and November, the difference between the lowest and
highest risk being 18%. Since colorectal cancer should not have any daylight-related hormone dependent risk
determinants, a control cohort of 12,950 women with a diagnosis of colorectal cancer in the same calendar
period was studied in a similar way. The survival pattern by month of diagnosis among the colorectal cancer
patients was similar to that among breast cancer patients, indicating that general factors associated with the
health behaviour of women and the health services (such as holidays) rather than biological factors may cause
seasonal variations in survival of cancer patients.
Seasonal variations in survival of breast cancer patients have
been described in New Zealand (Mason et al., 1990) and
Finland (Joensuu & Toikkanen, 1991). Differences in patient
series, methods of data acquisition, and seasons in the
opposite hemispheres make direct comparisons between these
series difficult, but evidently the variations did not appear
during the same seasons (Joensuu & Toikkanen, 1991). Some
authors have found no seasonal variation in survival of
breast cancer patients (Galea & Blamey, 1991).
As a consequence of the results of a city-based study
(Joensuu & Toikkanen, 1991), we decided to carry out a
nationwide survival study of female patients with breast or
colorectal cancer. The aim of the study was to establish
whether there were indeed variations in survival of cancer
patients depending on the month of diagnosis. Such varia-
tions might be explained by differences in patient delay and
health services due to, e.g. summer holidays, or by differences
in the biology of the host or the disease. The former theory
would be supported, if women whose breast cancers were
diagnosed in the months associated with unfavourable sur-
vival rates, had more advanced stage of the disease at diag-
nosis than women diagnosed in other months.
The comparison between breast cancer and colorectal
cancer was made in order to determine, if the proposed
daylight-related hormonal factors, such as seasonal changes
in the function of the pineal gland affecting melatonin prod-
uction, might explain the variation in the survival pattern
(Mason et al., 1990).
Patients and methods
The population-based, nationwide Finnish Cancer Registry
has been functioning since 1953. All hospitals, physicians and
pathological laboratories are required to notify the Registry
of all cancer cases that come to their attention. The Registry
also receives information from all death certificates in which
a cancer diagnosis is mentioned.
Between 1956 and 1985 32,807 female breast cancer
patients and 12,950 female colorectal cancer patients were
diagnosed in Finland and reported to the Registry with a
known month of diagnosis and stage. Patients whose month
of diagnosis or stage at diagnosis was not known, those who
were only known from their death certificate, and those
whose tumours were diagnosed at autopsy were not included.
The date of diagnosis in the Registry data base is defined as
the date on which there is enough clinical information to
justify the diagnosis of cancer.
Age, calendar period of diagnosis, and stage-specific
incidence rates for breast cancer were calculated using
person-years for the total Finnish female population pro-
vided by the Population Registry of Finland. The patients
were followed up until death or emigration through the files
of the Central Statistical Office of Finland. The follow-up
came to an end at either the date of death or emigration of
the patient, or on the closing day of December 31, 1989,
whichever occurred first. The follow-up was complete.
Relative survival rates (RSR) were calculated using a com-
puter program package (Hakulinen & Abeywickrama, 1985)
designed specifically for this purpose. Relative instead of
observed survival rates were used to avoid confounding by
the competing causes of death.
The excess risk of death attributable to cancer was defined
as the difference between mortality in the patient group and
mortality in a corresponding general population without
cancer (comparable in terms of sex, age, and period of
diagnosis). The relative excess risk of death (RR) was defined
as the ratio of the excess risks of death among patients
diagnosed in different months. To obtain the best possible
estimates for the RRs between different months of diagnosis,
we used a life-table proportional hazards model based on
annual relative survival rates for the first five follow-up years
and GLIM statistical software (Hakulinen & Tenkanen,
1987). To control for confounding, a model including all
available prognostic factors (age and stage at diagnosis,
period of diagnosis, follow-up year), and their significant
interaction terms was constructed before fitting the month of
diagnosis variable.
In the process offitting the model, the RR for January was
designated as the reference risk (with which the RRs of the
other months were compared, and for which a confidence
interval cannot be calculated). However, for the purpose of
this study, the mean of the RRs was defined as unity in order
to clarify the graphic image of the risk differences. To deter-
mine the significance of the contribution of each variable to
the model, the differences in deviance between hierarchical
models were compared with the corresponding differences in
the degrees of freedom using the chi-square distribution. All
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variables were categorical. Period categories were 1956-1965,
1966-1975 and 1976-1985. Age categories were 0-49,
50-64 and 65-99 years. Stage was divided into localised and
non-localised disease.
Results
The incidence of localised breast cancer varied more by the
month of diagnosis than that of non-localised tumours. In
the periods 1966-1975 and 1976-1985 the incidence of
localized tumours was lowest in July (Figure 1).
The five year cumulative relative survival rate (RSR) for
breast cancer patients diagnosed in July to September was
lower than that for patients diagnosed in other months when
not stratified by stage or period (Figure 2). After adjusting
for the available prognostic factors (stage, period, age, and
follow-up year), the month of diagnosis was a significant
(P<0.05) prognostic factor for breast cancer patients (Table
I). The risk of death was highest when the diagnosis was
made in August (RR = 1.10, 95% confidence interval
0.99-1.21) and lowest in March (RR = 0.93, 95% CI
0.84-1.02, Figure 3) corresponding to unadjusted 5-year
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cumulative RSRs of 63.0% (95% CI 60.8-65.2%) and
67.8% (95% CI 65.8-69.8%), respectively (Figure 2). None
of the prognostic variables had significant interactions with
the month of diagnosis.
The pattern of the risk of death by the month of diagnosis
for the female colorectal cancer patients was very similar
(Figure 3): the risk of death was highest when the diagnosis
was made in August (RR= 1.08, 95% CI 0.95-1.22) and
lowest in October (RR = 0.90, 95% CI 0.79-1.03). However,
owing to the smaller size of the cohort, the month of diag-
nosis as a prognostic factor did not quite reach statistical
significance after adjusting for the other factors (Table II).
The unadjusted 5-year cumulative RSR for the colorectal
cancer patients was 33.8% (95% CI 30.4-37.1%) for those
diagnosed in August, and 42.1% (95% CI 38.5-45.7%) for
those diagnosed in October.
Disussion
The unadjusted 5-year cumulative RSR for the breast cancer
patients was lowest in July, which first seemed to be
explained by the low incidence rate of localised tumours in
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Figure 1 Incidence of breast cancer among women in Finland by stage at diagnosis, and by period and month of diagnosis.
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Figure 2 Five-year cumulative relative survival rates of female breast cancer patients diagnosed in Finland for total cohort, and by
stage at diagnosis, and by period and month of diagnosis.
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Table I Results of fitting generalised linear models to the annual relative survival rates
for the first five follow-up years of 32,807 female breast cancer patients in Finland
diagnosed in 1956-1985
Differenceb in
Model Deviance DP Deviance DF
1. Constant 7185.1 1079
2. Model 1 + STAGE 2419.3 1078 4765.8*** 1
3. Model 2+ PERIOD 1809.7 1076 609.6*** 2
4. Model 3+AGE 1574.8 1074 234.9*** 2
5. Model 4+FUC 1503.9 1070 70.9*** 4
6. Model 5+FU.STAGEd 1289.0 1066 214.9*** 4
7. Model 6+FU.AGE 1180.6 1058 108.4*** 8
8. Model 7+FU.PERIOD 1112.7 1050 67.9*** 8
9. Model 8 + STAGEPERIOD 1045.5 1048 67.2*** 2
10. Model 9+ MONTH' 1025.3 1037 20.3* 11
Significance of term inclusion: *** = P<0.001, * = P<0.05. aDF: Degrees of freedom.
bCompared with the model to which a new term is added. cFU: Follow-up year after
diagnosis. dInteraction term. eMonth of diagnosis.
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Figure 3 Relative excess risk of death by month of diagnosis among female breast and colorectal cancer patients diagnosed in
Finland in 1956-1985. 95% confidence intervals are given for breast cancer (January = reference month).
Table II Results of fitting generalised linear models to the annual relative survival rates
for the first five follow-up years of 12,950 female colorectal cancer patients in Finland
diagnosed in 1956-1985
Differenceb in
Model Deviance DP' Deviance DF
1. Constant 8468.6 1076
2. Model 1+ STAGE 3563.5 1075 4905.1*** 1
3. Model 2+FUC 1901.7 1071 1661.8*** 4
4. Model 3+PERIOD 1654.0 1069 247.7*** 2
5. Model 4+AGE 1458.4 1067 195.6*** 2
6. Model 5 + STAGE.PERIODd 1395.0 1065 63.4*** 2
7. Model 6+STAGE.FU 1329.8 1061 65.2*** 4
8. Model 7+STAGE.AGE 1314.0 1059 15.8*** 2
9. Model 8+ FU.AGE 1264.7 1051 49.3*** 8
10. Model 9+ MONTH' 1245.1 1040 19.6 11
Significance of term inclusion: **=P<0.001. aDF: Degrees of freedom. bCompared
with the model to which a new term is added. cFU: Follow-up year after diagnosis.
dinteraction term. 'Month of diagnosis.
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July. However, after adjustment for stage, age, period, and
follow-up year, the month of diagnosis was still a significant
prognostic factor. The adjusted risk ratios showed that
August, not July, was the month related to the worst prog-
nosis. This result underlines the importance of using proper
statistical methods instead of relying on crude survival rates.
According to our results, day-light related hormonal fac-
tors are not likely explanations for the differences in the
survival pattern by the month of diagnosis of breast cancer
patients. If there was a biological mechanism (hormonal or
other) affecting the aggressiveness of cancer growth in a
seasonal rhythm, subclinical tumours should become clinical
during the rapid growth period more often than during the
rest of the year. The incidence of those tumours affected by
such a factor should be higher during the rapid growth
period, and the incidence of those unaffected should remain
constant throughout the year. Thus, a peak in the overall
incidence should appear in the period of rapid growth. This
peak would be likely to consist of both localised and non-
localised tumours. According to our results, however, fewer
breast cancers than on the average were detected during the
summer months associated with the worst prognosis (Figures
1 and 2).
Since a similar monthly pattern in survival rates was seen
among breast and colorectal cancer patients, it would appear
that season-related hormonal factors, such as season-
dependent excretion of melatonin, do not play any major
explanatory role. The process leading to a diagnosis ofbreast
cancer is very different from that of colorectal cancer, and
currently there is little evidence that the hormonal factors
affecting the prognosis of breast cancer patients would affect
patients with colorectal cancer in the same way.
Early breast cancers may be found incidentally by the
medical personnel or by screening. If these functions
accumulate at selected times instead of being evenly spread
throughout the year, seasonal variation in both the detection
and survival rates of cancer patients may occur. Even though
the health care system for cancer diagnostics and treatment
should, in principle, function evenly throughout the year, it
often does not. In summer health care resources are limited
owing to the holidays of the health care personnel (the most
common month for the four to five week holidays in Finland
is July, although both June and early August are also quite
popular). For this reason the number of incidentally found
tumours should be reduced during the holiday months. This
might be reflected by our results indicating that the incidence
of local breast cancer was lowest in July (Figure 1).
Temporary, less experienced substitute personnel may also
contribute to the lower survival rates for patients diagnosed
in the summer months: minor signs and symptoms might not
lead to a diagnosis of cancer, as they would in other months
when the health care system is fully operational, and for the
same reason, the quality of treatment may be lower in sum-
mer.
The variation in the survival pattern may be partly
explained by patient delay. Some women may hesitate to go
to their doctor in summer, except for alarming symptoms,
because the visit may interrupt or even spoil their holidays.
Some ofthe small tumours with less symptoms, and probably
with better prognosis, might not be diagnosed in summer,
and some of the tumours diagnosed in August or September
may be those with a delayed diagnosis from the summer
months, and thus, with a poorer prognosis.
Because of the large number of breast cancer patients in
our study, even small survival differences reach statistical
significance. In the case of breast cancer patients, the
difference in the 5-year cumulative RSR between the month
with the best prognosis and that with the worst was 4.8%
units, and the corresponding figure for the colorectal cancer
patients was 8.3% units. These figures can be interpreted in a
following way: 1,182 patients died of the 2,657 breast cancer
patients diagnosed in August during the study period
1956-1985 as only 316 deaths were expected, yielding 866
excess deaths among these patients. If the (stage adjusted)
observed and expected 5-year cumulative survival rates of
patients diagnosed in March were used for patients diag-
nosed in August, only 761 excess deaths would have occur-
red. The difference in the number ofexcess deaths was 105 or
12%. For colorectal cancer patients a simnilar calculation
reveals 60 or 10% more excess deaths among those patients
diagnosed in August as compared with those diagnosed in
October.
It is likely that general factors associated with the health
services and the health behaviour of women rather than
biological factors cause these differences. This result should
inspire clinicians to consider, if the quality of care in each
individual clinic could be improved in summer.
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